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Background: Hypertension is often preceded by cardiac structural abnormalities. Thus, 
we assessed whether high-sensitivity cardiac troponin-T (hs-cTNT), a marker of chronic 
subclinical myocardial damage, can identify persons at risk for hypertension or its 
representative complication, left ventricular hypertrophy (LVH). 
 
Methods: We studied 6,516 ARIC Study participants, free of prevalent hypertension and 
cardiovascular disease at baseline (1990-1992). We examined the association of baseline 
hs-cTNT categories with incident diagnosed hypertension (defined by self-report of a 
diagnosis or medication use during a maximum of 19.9 years of follow-up) and with 
incident visit-based hypertension (defined by self-report, medication use, or measured BP 
>140/90 mmHg over 6 years).  
 
Results: Relative to hs-cTNT <5 ng/L, adjusted hazard ratios for incident diagnosed 
hypertension were 1.16 (95% CI 1.08, 1.25) for persons with hs-cTNT 5-8 ng/L, 1.29 
(1.14, 1.47) for hs-cTNT 9-13 ng/L, and 1.31 (1.07, 1.61) for hs-cTNT ≥14 ng/L (p-trend 
<0.001). Associations were stronger for incident visit-based hypertension. These 
associations were driven by higher relative hazard in normotensive persons (relative to 
those with prehypertension, p-interaction=0.001). Baseline hs-cTNT was also strongly 
associated with incident LVH by electrocardiography over 6 years (e.g. adjusted HR 5.19 
[1.49-18.08] for hs-cTNT ≥14 ng/L vs <5 ng/L). Findings were not appreciably changed 
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after accounting for competing deaths or adjustment for baseline BP levels or N-terminal 
prohormone of brain natriuretic peptide. 
 
Conclusion: In an ambulatory population with no history of cardiovascular disease, hs-
cTNT was associated with incident hypertension and risk of LVH. Further research is 
needed to determine whether hs-cTNT can identify persons who may benefit from 





Kunihiro Matsushita, M.D., Ph.D 
 














I would like to thank my advisor, Dr. Elizabeth Selvin, for her dedication, intelligence, 
resourcefulness, generosity, and mentorship. Sincere thanks also to my amazing clinical 
mentors, Dr. Roger Blumenthal and Dr. Steven Schulman. 
I wish to thank my wife, Katherine, for her loving patience and big heart. 
In completing this work, I am also indebted to my co-investigators on this project; Yuan 
Chen MS; Vijay Nambi MD PhD; Christie M. Ballantyne MD; A. Richey Sharrett MD 
DrPH; Lawrence J. Appel MD MPH; Wendy S. Post MD MS; and Kunihiro Matsushita 
MD PhD. 
Finally, I want to thank the staff and participants of the ARIC study for their important 
contributions.  
I note that this research was supported by NIH/NIDDK grant R01DK089174 to my thesis 
supervisor, Dr. Elizabeth Selvin. The Atherosclerosis Risk in Communities Study is 
carried out as a collaborative study supported by National Heart, Lung, and Blood 
Institute contracts (HHSN268201100005C, HHSN268201100006C, 
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, 































LIST OF TABLES 
Table 1- page 20. Characteristics of the Study Population (ARIC participants without 
cardiovascular disease or diagnosed hypertension): Overall and According to categories 
of high sensitivity cardiac troponin T (hs-cTNT, ng/L) at baseline (1990-1992). 
Table 2- page 22. Crude incidence rates and adjusted hazard ratios (95% confidence 
intervals) for incident hypertension outcomes, according to baseline high sensitivity 
cardiac troponin T. 
Table 3- page 23. Crude incidence rates and adjusted hazard ratios (95% confidence 
intervals) for incident diagnosed hypertension, according to baseline categories of high 
sensitivity cardiac troponin T: further stratified by baseline blood pressure. 
Table 4- page 25. Adjusted Hazard Ratios (95% confidence intervals) for the secondary 
outcome of incident left ventricular hypertrophy over 6 years of follow-up by baseline 
high sensitivity cardiac troponin T among persons free of baseline cardiovascular disease 
or hypertension. 
 
LIST OF FIGURES 
Figure 1- page 26. Adjusted hazard ratio (95% confidence interval) of A) incident 
diagnosed hypertension and B) incident visit-based hypertension, according to baseline 
hs-cTNT modeled as linear splines (knots at 5, 8 and 13 ng/L) with background 
histogram of hs-cTNT in the study sample of ARIC subjects without baseline 









Hypertension remains a major cause of heart disease and stroke, with approximately 1 in 
3 U.S. adults currently diagnosed as hypertensive and a further 6-10% of Americans 
estimated to have undiagnosed hypertension. 1 In addition, a significant proportion of 
those with diagnosed hypertension have poorly controlled blood pressure (BP). 2, 3 Thus, 
there is a need to identify persons at risk either for progressing to clinically overt 
hypertension or developing complications of this disease. In particular, BP can be 
improved by more aggressive lifestyle and dietary changes in those with both 
prehypertension and overt hypertension. 4 
The onset of hypertension is an insidious process that often occurs over many years and 
is often preceded by altered diurnal BP patterns and prehypertension. 5, 6 While 
hypertension is diagnosed using defined BP thresholds, risks associated with elevated BP 
occur on a continuous spectrum. Indeed, even early, pre-hypertensive, BP abnormalities 
can induce structural heart changes7, potentially affording the opportunity to both detect 
persons at risk for overt hypertension and to initiate timely preventive strategies. 8 Prior 
studies have focused on the association between subclinical structural heart disease, 
particularly left ventricular hypertrophy (LVH), and subsequent development of 
hypertension. While these studies have confirmed that baseline LVH, measured by both 
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echocardiography9, 10 and by cardiac MRI11, is associated with incident hypertension, 
these imaging modalities are often impractical and too costly for routine screening.  
New highly sensitive cardiac troponin T (hs-cTNT) assays have great potential as 
noninvasive laboratory-based markers of subclinical myocardial damage. These assays 
can detect subclinical myocardial damage in a significant proportion of persons who are 
free of known cardiovascular disease in the community. 12, 13 Interestingly, detectable 
levels of hs-cTNT appear to be more strongly linked to structural heart disease and its 
risk factors than to epicardial coronary artery disease. 13-15 Thus, hs-cTNT screening may 
be of particular use in persons at risk for clinically apparent hypertension and other 
cardiovascular endpoints. Hs-cTNT may also help identify individuals who are at risk of 
developing hypertension and/or hypertensive end-organ damage, such as LVH.  
Thus, we sought to determine if hs-cTNT could identify persons at risk for subsequent 
hypertension in a large U.S. community-based cohort, the Atherosclerosis Risk in 










Study Population  
The ARIC Study is a prospective cohort of 15,792 participants enrolled between 1987 
and 1989 from four U.S. communities (Forsyth Country, North Carolina; Jackson, 
Mississippi; Minneapolis, Minnesota; and Washington County, Maryland). 16 We 
measured hs-cTNT in samples collected from all participants at ARIC visit 2, which took 
place from 1990 to 1992 and represents the baseline for this current analysis. Of the 
14,348 persons who attended visit 2, we excluded all persons with prevalent diagnosed 
hypertension (n=6,334), those who had coronary heart disease (CHD, including silent 
myocardial infarction detected by electrocardiogram [ECG]), stroke, or heart failure at or 
prior to visit 2 (n=177), or those who were missing variables of interest (n=1,321) 
(Supplemental Figure 1, Appendix). Thus, 6,516 persons were included in the analysis 
evaluating our primary outcome of incident diagnosed hypertension (self-report of 
diagnosis or medication use during annual telephone follow-up). In our secondary 
analysis of incident visit-based hypertension, we further excluded 599 persons with 
measured BP at baseline >140/90 mmHg (undiagnosed hypertension) and 242 persons 
without available BP measurement data, for an analytic study sample of 5,675 persons. In 
our analysis of incident LVH, we further excluded 44 persons with baseline LVH by 
ECG for an analytic sample of 5,631 (Supplemental Table 1, Appendix). Institutional 
review boards at each clinical site reviewed the study and informed consent was obtained 




Measurement of hs-cTNT and other exposure variables 
We measured hs-cTNT in stored serum samples, collected at visit 2, using a Roche 
Elecys 2010 Analyzer (Roche Diagnostics, Indianapolis, Indiana) at the University of 
Minnesota in 2012-2013. Coefficient of variation for hs-cTNT was 6.0% at a 
concentration of 25 ng/L. Participants self-reported smoking status. Plasma lipid 
concentrations and body weight and height for body mass index (BMI) were determined 
using standardized protocols. Glucose was measured using the hexokinase method.17 
Diagnosed diabetes was defined as a self-reported physician diagnosis of diabetes or 
current use of diabetic medications. Glomerular filtration rate was estimated using serum 
creatinine and the CKD-EPI 2009 equation.18 N-terminal prohormone-brain natriuretic 
peptide (NT-proBNP) was measured in stored serum samples from visit 2 on a Roche 
Elecsys 2010 Analyzer using a sandwich immunoassay method (Roche Diagnostics, 
Indianapolis, Indiana).   
 
Follow-up for outcomes of interest 
Participants were contacted annually via telephone, with follow-up currently available 
through March 2012. Incident diagnosed hypertension was assessed during these annual 
telephone calls using the following questions: “Has a doctor ever said you had high blood 
pressure?”, or “Since we last contacted you has a doctor said you had high blood 
pressure?”, and “Did you take any medications during the past two weeks for high blood 
pressure?”. After visit 2, ARIC participants also completed two further follow-up study 
examinations, visit 3 (1992-1995) and visit 4 (1996-1998). During these follow-up study 
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visits, BP was recorded as the mean of at least 2 seated measurements using a manual 
random-zero sphygmomanometer.  
We also evaluated the association between hs-cTNT and a well-known sequela of 
hypertension, LVH. This secondary outcome was assessed at visits 3 and 4, in persons 
free of both hypertension and LVH at visit 2, using resting 12-lead electrocardiograms 
and defined by Cornell criteria. 19   
 
Statistical Analyses 
Characteristics for the study population were presented according to categories of hs-
cTNT (<5, 5-8, 9-13, or ≥14 ng/L) at baseline (visit 2, 1990-1992). While the hs-cTNT 
assay used can measure concentrations of troponin T as low as 3 ng/L13, values <5 ng/L 
are measured with reduced precision and represent the typical lower cut-point in 
categorical analyses. Values ≥14ng/L represent approximately the 90th percentile of the 
ARIC population and correspond to the 99th percentile value for a “healthy” reference 
group of persons aged 20-70 years. 20  
The primary outcome of interest was incident diagnosed hypertension during a maximum 
of 19.9 and a median of 12 years of follow-up. Incident cases were identified at ARIC 
study visits 3 and 4 and, thereafter, by annual telephone contact with all participants. 
Time of incident diagnosed hypertension was the date when participants first reported 
diagnosis of or treatment for hypertension. We evaluated visit-based hypertension during 
a maximum of 8.7 and a median of 6 years follow-up as a secondary outcome. Visit-
based cases of hypertension were identified by mean systolic BP ≥140mmHg or mean 
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diastolic BP ≥90mmHg, self-reported physician diagnosis, or medication use at visits 3 
(1993-1995) or 4 (1996-1998). For both hypertension endpoints, we also conducted 
analyses stratified by baseline BP category (normotensive [BP ≤120 mmHg systolic and 
≤80 mmHg diastolic] or pre-hypertensive [BP >120 mmHg <140 mmHg systolic and/or 
>80 mmHg <90 mmHg]). Finally, we evaluated the association between baseline hs-
cTNT and incident LVH at visit 3 (1993-1995) or visit 4 (1996-1998) among persons free 
from both hypertension and LVH at visit 2 (1990-1992). 
We used Cox proportional hazards regression models for the primary outcome of 
diagnosed hypertension and discrete proportional hazards (cloglog) regression models for 
both secondary outcomes (visit-based incident hypertension or incident LVH) to estimate 
adjusted hazard ratios (HRs) for the association between baseline hs-cTNT and these 
outcomes. We modeled hs-cTNT as a categorical (<5 [reference], 5-8, 9-13, or ≥14 ng/L) 
and continuous exposure (log-transformed). In analyses with hs-cTNT as a continuous 
exposure, hs-cTNT was modeled as untransformed or log-transformed and either 
truncated at <3ng/L (the limit of measurement) or with unmeasurable levels assigned a 
value of half the lower limit of measurement (1.5ng/L). 21 Using Martingale residuals to 
assess fit, the log-transformed visit 2 hs-cTNT without truncating fit the continuous 
models best. P-values for linear trend among hs-cTNT categories were obtained by 
assigning the median hs-cTNT value in the above categories of hs-cTNT and modeling 
this ordinal variable continuous. For all models, we verified the proportionality of the 
hazards with Schoenfeld residuals.  
Models were adjusted for age (years), race-center (whites-Washington County; whites-
Minneapolis; blacks-Jackson; blacks-Forsyth County, whites-Forsyth County), sex (male 
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or female), body mass index (kg/m2), smoking (current; former; never), LDL-cholesterol 
(mg/dL), HDL-cholesterol (mg/dL), triglycerides (mg/dL), estimated glomerular filtration 
rate (mL/min/1.73m2), current lipid-lowering medication use (yes or no), LVH (yes or 
no), and diagnosed diabetes (yes or no). We tested for interactions by age, sex, and race. 
In sensitivity analyses we additionally adjusted for baseline (visit 2) blood pressure or 
NT-proBNP levels. Because baseline hs-cTNT is associated with all-cause mortality, 
cardiovascular death, and sudden cardiac death13, 15, 22-24, we also conducted sensitivity 
analyses with a competing risk regression method (Fine-Gray approach) using a 
cumulative incidence function to account for intervening deaths. 25 
Finally, we also modeled hs-cTNT using linear splines in fully-adjusted Cox models for 
both incident diagnosed and incident visit-based hypertension, with knots at hs-cTNT 
concentrations of 5, 8 and 13 ng/L (figures truncated at the 99th percentile), These models 
are shown graphically and overlaid on histograms showing the distribution of hs-cTNT in 
the study population. All analyses were performed using Stata version 13.0 (College 










In our community-based study population of subjects without a history of cardiovascular 
disease and free from baseline hypertension, persons with higher baseline hs-cTNT were 
more likely to be older, male, black, pre-hypertensive, obese, have higher HbA1c, and 
have reduced kidney function (Table 1).   
During a maximum of 19.9 and a median 12 years of follow-up, 68% (n=4421) of the 
study sample developed our primary endpoint; incident diagnosed hypertension. Of these, 
70% (n=3108) had hs-cTNT <5 ng/L at baseline, 21% (n=936) had hs-cTNT 5-8 ng/L, 
6% (n=281) had hs-cTNT 9-13 ng/L, and 2% (n=96) had hs-cTNT ≥14 ng/L (Table 2). 
Crude incidence rates (per 1,000 person/years) of diagnosed hypertens ion were 54 in 
those with hs-cTNT <5 ng/L, 64 with hs-cTNT 5-8 ng/L, 73 with hs-cTNT 9-13 ng/L, 
and 74 in persons with baseline hs-cTNT ≥14 ng/L. 
After multivariable adjustment, baseline hs-cTNT remained significantly associated with 
incident diagnosed hypertension (Table 2). Specifically, relative to those with 
undetectable hs-cTNT at baseline, persons in the higher categories of hs-cTNT had a 
higher adjusted risk of hypertension. Similar results were found for log-hs-cTNT 
modeled as a continuous variable. A continuous and roughly linear association between 
baseline hs-cTNT and incident diagnosed hypertension is shown graphically in Figure 1a.  
The association between baseline hs-cTNT (both by category and as a continuous 
exposure) and our secondary outcome of incident visit-based hypertension was stronger 
than that for incident diagnosed hypertension (Table 2, Figure 1b). Further, in analyses 
stratified by baseline blood pressure category (normotensive or prehypertensive), we 
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observed that the overall association between hs-cTNT and both incident hypertension 
outcomes appeared to be largely driven by robust associations in persons who were 
normotensive at baseline (p-for-interaction=0.04 for diagnosed hypertension and p-for-
interaction=0.001 for visit-based hypertension) (Table 3 and Supplemental Table 2 in the 
Appendix). Associations between hs-cTNT and both incident diagnosed and visit-based 
hypertension were largely unchanged after further adjustment for baseline blood pressure 
or NT-proBNP (Supplemental Table 3 in the Appendix). Interactions for the association 
of hs-cTNT and risk of hypertension by age, gender, and race were all were non-
significant (all p-values-for-interaction >0.10). 
There were 532 competing deaths for the primary outcome of incident diagnosed 
hypertension over 12-years follow-up, but only 57 competing deaths for the secondary 
outcome of incident visit-based hypertension over 6-years. In competing risk models, the 
association between hs-cTNT and incident diagnosed hypertension remained significant 
but was somewhat weakened in the hs-cTNT 5-8 ng/L and 9-13 ng/L categories and was 
no longer significant in those with baseline hs-cTNT ≥ 14 ng/L (Table 2).  In contrast, 
results for the 6-year incident visit-based hypertension were similar in the Fine-Gray 
competing-risk models 
Finally, we found that, relative to hs-cTNT of <5ng/L, persons in higher categories of hs-
cTNT had a highly significant 6-year risk of incident LVH by ECG: HR, 2.29 (95% CI 
1.24-4.26) for hs-cTNT 5-8ng/L, HR, 2.94 (95% CI 1.14-7.58) for hs-cTNT 9-13ng/L 




DISCUSSION AND CONCLUSIONS 
In this large community-based study population of U.S. adults, free of baseline 
hypertension and cardiovascular disease, we found that hs-cTNT was independently 
associated with subsequent development of hypertension, defined either by diagnosed 
cases (self-reported diagnosis or medication use) or by objective office measurement of 
BP (which also captured undiagnosed hypertension), and incident LVH by ECG. Our 
findings were similar by age, race and gender. Our results suggest that chronic subclinical 
myocardial damage, detected by elevated hs-cTNT, may precede the development of 
hypertension in the general population and that this novel biomarker of cardiac damage 
may have utility for identifying persons at future risk for hypertension and hypertensive 
end-organ damage.  
Prior studies have reported the cross-sectional association between established 
hypertension and prevalent hs-cTNT elevations15, 26-28. However, to our knowledge, this 
is the first study to evaluate the association between preceding subclinical myocardial 
damage, as measured by hs-cTNT, and subsequent risk of hypertension over prospective 
follow-up. Notably, this association was strongest for persons who had baseline normal 
BP readings (in contrast to those with pre-hypertension). Notably, the vast majority of 
individuals with prehypertension go on to develop hypertension, irrespective of baseline 
hs-cTNT. Therefore, the absolute risk of hypertension is very high in this entire sub-
group, helping to explain why the relative impact of hs-cTNT was non-significant in 
those with prehypertension. 
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While the exact pathway linking hs-cTNT to incident hypertension is unclear, a number 
of considerations are worth discussing. Elevated BP develops over time along a spectrum 
from normotension, to abnormal diurnal patterns of BP, to pre-hypertension, and then, 
ultimately, to clinical hypertension5. It is known that abnormalities in cardiac structure 
can occur long before the diagnosis of overt hypertension is made in the clinic5, 9, 29. 
Based on our results, it is possible that these early BP aberrations cause myocardial 
damage, leading to elevated hs-cTNT, before clinically overt hypertension is recognized. 
Compatible with this hypothesis, it has been shown elsewhere that “non-dippers” (an 
abnormal diurnal BP pattern where sleep systolic BP fails to decrease >10% from 
daytime systolic BP and a known risk-factor for subsequent hypertension6), are more 
likely to have prevalent detectable troponin levels by hs-cTNT assays30.  
In addition, BP is highly variable and its true hemodynamic load cannot easily be 
captured by single office measurements (which are subject to misclassification error). 
Thus, it is also possible that the association between hs-cTNT and subsequent 
hypertension in ARIC could be a manifestation of the well-known phenomenon of 
“masked hypertension,” the clinical condition in which a patient’s office BP level is 
<140/90 mm Hg but home or ambulatory readings are in the hypertensive range31. 
Masked hypertension occurs in over 10% of the adult population31, 32 and is known to 
result in end organ damage33, 34.  
Further, we found that elevated hs-cTNT was also a risk factor for the development of 
LVH in persons without baseline hypertension or clinical cardiovascular disease 
(including silent MI). This suggests that hs-cTNT may also predict future sequelae of 
hypertension and is consistent with our hypothesis that elevated hs-cTNT may reflect 
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occult BP abnormalities in some individuals. Indeed, prior case-control data suggest that 
hs-cTNT is also associated with subsequent albuminuria in hypertensive patients. 35 It is 
also worth noting that hs-cTNT could potentially be contributing more directly to the 
development of hypertension. For example, elevated hs-cTNT has been linked with 
arterial stiffness in diabetics36. 
Our results were robust to multiple sensitivity analyses. Standard Cox proportional-
hazards models assume that persons censored (including those censored for death) prior 
to the end of follow-up have the same probability of incident hypertension as similar 
persons who remain under-observation. However, in persons who die, the development of 
hypertension cannot be observed. In this context, the Fine-Gray regression results, which 
account for interval deaths, are important to determine the ‘real-world’ impact of hs-
cTNT screening in persons at risk for hypertension. In these Fine-Gray models, we found 
that the association between hs-cTNT and incident diagnosed hypertension (an endpoint 
with longer follow-up and increased interval accrual of deaths) was attenuated, 
particularly in the ≥14 ng/L category. 
Our findings may have implications for future clinical practice. Specifically, 
normotensive persons with elevated hs-cTNT are at risk for subsequent hypertension and 
may benefit from evaluation for masked hypertension and from more intensive lifestyle 
BP interventions to reduce the likelihood of developing this morbid disease. Further 
research is necessary to confirm whether hs-cTNT could be useful in screening those at 
risk for hypertension.  
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This analysis has some limitations. This study was observational and, thus, may be 
subject to residual confounding. We do not have ambulatory BP recordings to determine 
whether or not masked hypertension or abnormal diurnal values were present in persons 
with elevated hs-cTNT. Cases of diagnosed hypertension were identified by self- report 
of diagnoses or medication used during annually follow-up; however, similar results were 
obtained in our analyses of visit-based hypertension (incorporating undiagnosed cases 
identified by elevated blood pressured obtained during the clinical visit). Strengths of the 
study include the large sample size, bi-racial population, and rigorous measurement of 
cardiovascular risk factors. 
In conclusion, elevated hs-cTNT in the general population, particularly among persons 
with normal blood pressure, identifies persons at risk for subsequent hypertensio n or 
LVH. Further studies are necessary to determine whether subclinical myocardial damage 
in these settings is due to masked hypertension or abnormal diurnal variability in BP. 
Elevated hs-cTNT in low-risk ambulatory populations may prove to be clinically useful 
in identifying persons at risk for hypertension, affording the opportunity both to consider 
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Table 1. Characteristics of the Study Population (ARIC participants without cardiovascular 
disease or diagnosed hypertension): Overall and According to categories of high sensitivity 
cardiac troponin T (ng/L) at baseline (1990-1992) 
 
 Overall Stratified by hs-cTNT 
  <5 ng/L 5-8 ng/L 9-13 ng/L ≥14 ng/L 







Age, years 56.1 (5.6) 55.3 (5.4) 57.5 (5.7) 59.2 (5.6) 58.5 (5.7) 
Male %  44.1 35.8 61.4 74.2 76.1 
Black %  17.3 16.4 17.5 25.3 23.9 
Current smoker %  22.8 24.8 17.8 16.9 20.1 
Systolic blood pressure mmHg 115.2  
(15.1) 
113.8 (14.6) 117.6 (15.5) 120.4 (14.9) 124.0 (19.4) 
Diastolic blood pressure mmHg 69.7 (9.1) 69.3 (9.0) 70.7 (9.4) 70.8 (9.1) 70.7 (9.6) 
Hypertension categories (% )      
      Normotension  
      (BP <120/80 mmHg) 
66.3 69.6 59.6 55.5 48.5 
      Prehypertension  
      (BP 120-139/80-89 mmHg) 
27.4 25.2 32.2 34.6 35.1 
      Undiagnosed hypertension 
      (BP >140/90mmHg)* 
6.3 5.2 8.2 9.9 16.4 
LVH %  0.9 0.7 0.9 2.3 3.0 
BMI, kg/m2      
Normal weight %  (< 25) 39.0 41.3 33.4 32.6 29.9 
Overweight %  (25 - 30) 41.1 39.9 44.6 42.7 42.5 
Obese %  (> 30) 20.0 18.8 22.0 24.7 27.6 










LDL-cholesterol, mg/dL 131.8  
(35.9) 
131.5 (36.3) 132.9 (34.7) 131.1 (35.7) 131.2  
(37.1) 
HDL-cholesterol, mg/dL 51.5 (16.9) 52.8 (17.0) 48.4 (15.8) 47.1 (15.6) 49.3 (18.9) 
Triglyceride, mg/dL 120.6  
(61.0) 
118.8 (59.4) 125.5 (63.9) 123.1 (66.6) 126.5 
(67.9) 
Lipid Medicines %  3.3 3.4 3.5 2.1 1.5 
Diagnosed diabetes %  4.2 3.4 4.6 9.6 14.9 
eGFR <60 mL/min/1.73m2 (% ) 0.5 0.4 0.6 0.5 4.5 
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Estimates are mean (SD) or %, unless otherwise indicated. Hs-cTNT= high-sensitivity Troponin-
T, BP= Blood Pressure, LVH= left ventricular hypertrophy, BMI= body mass index, LDL= Low 
Density Lipoprotein, HDL= High Density Lipoprotein, eGFR= estimated Glomerular Filtration 
Rate. 
*This group was excluded for the visit-based hypertension outcome analysis 
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Table 2. Crude incidence rates and adjusted* hazard ratios (95% confidence intervals) for 
incident hypertension outcomes, according to baseline high sensitivity cardiac troponin T  
      


















Incident Diagnosed Hypertension  
Categories      







5-8 ng/L  1,317 936 
64.0  
(60.0-68.3) 
 1.16  
(1.08-1.25) 
 1.15  
(1.06-1.24) 
9-13 ng/L  384 281 
72.6  
(64.6-81.6) 
 1.29  
(1.14-1.47) 
 1.21  
(1.05-1.38) 
≥14 ng/L  134 96 
73.9  
(60.5-90.2) 




p-value for linear trend      <0.001 <0.001 
Continuous      







Incident Visit-based Hypertension  
Categories   
 
  







5-8 ng/L  1,130 351 
58.6  
(52.8-65.1) 
 1.15  
(1.01-1.30) 
 1.14  
(1.00-1.29) 
9-13 ng/L  306 120 
74.9  
(62.6-89.5) 
 1.32  
(1.08-1.61) 
 1.38  
(1.13-1.67) 
≥14 ng/L  100 41 
77.8  
(57.3-105.6) 
 1.49  
(1.09-2.05) 
 1.47  
(1.07-2.01) 
p-value for linear trend      <0.001 <0.001 
Continuous      








* Adjusted for age (years), race-center (whites-Washington County; whites-Minneapolis; blacks-
Jackson; blacks-Forsyth County, whites-Forsyth County), sex (male or female), body mass index 
(kg/m2), smoking (current; former; never), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
triglycerides (mg/dL), estimated glomerular filtration rate (mL/min/1.73m2), lipid-lowering 
medications (yes or no), left ventricular hypertrophy (yes or no), diagnosed diabetes (yes or no).  
†Cox regression for diagnosed hypertension outcome, cloglog regression for visit-based hypertension 
‡Fine-Gray regression model. 25 There were 532 interval deaths for the diagnosed hypertension 




Table 3. Crude incidence rates and adjusted* hazard ratios (95% confidence intervals) for 
incident diagnosed hypertension, according to baseline categories of high sensitivity cardiac 
troponin T: further stratified by baseline blood pressure (N=6,516)  
 
     








Incidence rate, per 







NORMOTENSIVE SUBGROUP (BP ≤120 mmHg systolic and ≤80 mmHg diastolic) 
Categorical   
 
  
<5 ng/L 3,259 1,892 42.4 (40.6-44.4) 1 (reference) 1 (reference) 
5-8 ng/L  785 480 47.9 (43.8-52.3) 









≥14 ng/L  65 41 54.1 (39.9-73.5) 




p-value for linear trend    <0.001 0.006 
Continuous      





PREHYPERTENSION  SUBGROUP (BP >120 <140 mmHg systolic and/or >80<90 mmHg diastolic) 
Categorical      
<5 ng/L 1,179 988 87.4 (82.1-93.0) 1 (reference) 1 (reference) 





9-13 ng/L  133 113 99.7 (82.9-119.9) 




≥14 ng/L  47 33 78.6 (55.9-110.6) 




p-value for linear trend    0.125 0.667 
Continuous      





UNDIAGNOSED HYPERTENSION  SUBGROUP (BP ≥140 mmHg systolic and/or ≥90mmHg diastolic)  
Categorical      
<5 ng/L 243 228 138.1 (121.3-157.3) 1 (reference) 1 (reference) 
5-8 ng/L  108 100 150.1 (123.4-182.6) 




9-13 ng/L  38 34 158.5 (113.2-221.8) 




≥14 ng/L  22 22 180.1 (118.6-273.5) 




p-value for linear trend    0.045 0.088 
Continuous      







* Adjusted for age (years), race-center (whites-Washington County; whites-Minneapolis; blacks-
Jackson; blacks-Forsyth County, whites-Forsyth County), sex (male or female), body mass index 
(kg/m2), smoking (current; former; never), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
triglycerides (mg/dL), estimated glomerular filtration rate (mL/min/1.73m2), current lipid-
lowering medication use (yes or no), left ventricular hypertrophy (yes or no), diagnosed diabetes 
(yes or no). Abbreviations as per Table 1. 
†Cox regression for diagnosed hypertension outcome                                                                         
‡Fine-Gray regression model. 25 There were 532 interval deaths for the diagnosed hypertension 































Table 4. Adjusted* Hazard Ratios (95% confidence intervals) for the secondary outcome of 
incident left ventricular hypertrophy over 6 years of follow-up by baseline high sensitivity 





















* Adjusted for age (years), race-center (whites-Washington County; whites-Minneapolis; blacks-
Jackson; blacks-Forsyth County, whites-Forsyth County), sex (male or female), body mass index 
(kg/m2), smoking (current; former; never), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
triglycerides (mg/dL), estimated glomerular filtration rate (mL/min/1.73m2), current lipid-
lowering medication use (yes or no), diagnosed diabetes (yes or no). Abbreviations as per Table 
1. 















 N  Events (n)  HR (95% CI) 
Categorical    
<5 ng/L 4109 30 
1 
(reference) 
5-8 ng/L 1121 17 
2.29 (1.24-4.26) 
9-13 ng/L 302 6 
2.94 (1.14-7.58) 
≥14 ng/L 99 3 
5.19 (1.49-18.08) 
p-value for trend   <0.001 
Continuous    
Log(hs-cTnT) 5,631 56 1.79 (1.27-2.52) 
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Figure 1. Adjusted* hazard ratio (95% confidence interval) of A) incident diagnosed 
hypertension and B) incident visit-based hypertension, according to baseline hs-cTnT 
modeled as linear splines (knots at 5, 8 and 13 ng/L) with background histogram of hs-











* Adjusted for age (years), race-center (whites-Washington County; whites-Minneapolis; blacks-
Jackson; blacks-Forsyth County, whites-Forsyth County), sex (male or female), body mass index 
(kg/m2), smoking (current; former; never), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
triglycerides (mg/dL), estimated glomerular filtration rate (mL/min/1.73m2), current lipid-
lowering medication use (yes or no), left ventricular hypertrophy (yes or no), diagnosed diabetes 
(yes or no). Abbreviations as per Table 1. 

























Supplemental Figure 1. Flow Chart of exclusion process for the main study sample 
used to assess the primary outcome of Diagnosed Hypertension, drawn from ARIC 























ARIC participants who attended 
visit 2 (1990-1992)  
n = 14,348 
Participants without hypertension 
or cardiovascular disease   
n = 7,837 
Main Analysis Study population,  
n = 6,516 
Participants with hypertension or cardiovascular events 
occurring at or prior to visit 2: 
6334 with hypertension 
177 with coronary heart disease (including silent MI by 
ECG), heart failure, or stroke 
 
923 Missing hs-cTnT 
159 Missing model covariates 
192 Missing follow-up for incident hypertension 
  47 Non-black or non-white race/ethnicity 
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Supplemental Table 1- Study Sample Exclusion Process for Secondary Outcomes of 
interest 
Exclusion Process Exclusion Population  
1- Visit-Based Hypertension   
Attended visit 2  14348 
 Missing hs-cTnT data at visit 2 923 13426 
  Prevalent diagnosed hypertension at or before visit 2 6334 7091 
   Prevalent undiagnosed hypertension at or before visit 2 599 6492 
    Prevalent CHD, HF, stroke  177 6315 
      Missing follow-up hypertension information after visit 2 192 6123 
       Missing follow-up BP information at visits 2 and 4 242 5881 
         Missing visit 2 variables of interest  159 5722 
          Non black or white, race-center exclusion 47 5675 
   
2- 6-year risk of incident LVH    
Attended visit 2  14348 
 Missing hs-cTnT data at visit 2 923 13426 
  Prevalent diagnosed hypertension at or before visit 2 6334 7091 
   Prevalent undiagnosed hypertension at or before visit 2 599 6492 
    Prevalent CHD, HF, stroke  177 6315 
      Missing follow-up hypertension information after visit 2 192 6123 
       Missing follow-up BP information at visits 2 and 4 242 5881 
         Missing visit 2 variables of interest  159 5722 
          Non black or white, race-center exclusion 47 5675 






















Supplemental Table 2. Crude incidence rates and adjusted* hazard ratios (95% 
confidence intervals) for incident visit-based hypertension, according to baseline 
categories of high sensitivity cardiac troponin T: further stratified by baseline blood 
pressure (N=5,479) 
 
* Adjusted for age (years), race-center (whites-Washington County; whites-Minneapolis; blacks-
Jackson; blacks-Forsyth County, whites-Forsyth County), sex (male or female), body mass index 
(kg/m2), smoking (current; former; never), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
triglycerides (mg/dL), estimated glomerular filtration rate (mL/min/1.73m2), current lipid-
lowering medication use (yes or no), left ventricular hypertrophy (yes or no), diagnosed diabetes 
(yes or no). Abbreviations as per Table 1. 
     




Baseline hs-cTNT  N 
 Events 
(n) 
Incidence rate, per 









NORMOTENSIVE  SUBGROUP  
(BP ≤120 mmHg systolic and ≤80 mmHg diastolic) 
Categorical   
 
  
<5 ng/L 3,088 515 29.8 (27.4-32.5) 1 (reference) 1 (reference) 
5-8 ng/L  753 156 37.5 (32.0-43.8) 




9-13 ng/L  200 57 52.4 (40.4-68.0) 









p-value for linear trend      <0.001 <0.001 
Continuous      






PREHYPERTENSION SUBGROUP  
(BP >120 <140 mmHg systolic and/or >80<90 mmHg diastolic) 
Categorical   
 
  
<5 ng/L 1,051 544 104.2 (95.8-113.3) 1 (reference) 1 (reference) 





9-13 ng/L  106 63 122.2 (95.5-156.5) 




≥14 ng/L  38 21 116.9 (76.2-179.3) 




p-value for linear trend      0.226 0.133 
Continuous      







†Cox regression for diagnosed hypertension outcome, cloglog regression for visit-based 
hypertension ‡Fine-Gray regression model. 1 There were 532 interval deaths for the diagnosed 









































Supplemental Table 3. Adjusted* Cox Hazard Ratios (HRs) for incident diagnosed 
hypertension (N=6,516) and for visit-based incident hypertension (N=5675) by 
baseline hs-cTnT status, with additional adjustment for either baseline mean BP or 
NT-proBNP 
 
Additional Correction for Baseline (Visit 2) Mean BP 
Diagnosed hypertension Visit Based hypertension 
Visit 2  









Visit 2  








<5 ng/L 4,681 3,108 1 (ref.)   <5 ng/L 
4,13
9 1,059 1 (ref.)   
5-8 ng/L  1,317 936 
 1.12  
(1.04-1.21) 0.004 5-8 ng/L  
1,13
0 351 
 1.16  
(1.07-1.25) <0.001 
9-13 ng/L  384 281 
 1.27  
(1.12-1.45) <0.001 9-13 ng/L  306 120 
 1.29  
(1.13-1.46) <0.001 
≥14 ng/L  134 96 
 1.20  
(0.98-1.48) 0.083 ≥14 ng/L  100 41 
 1.26  
(1.02-1.55) 0.032 
p-value for 
trend     <0.001   
p-value for 
trend     <0.001   
Log(v2 hs-










Additional Correction for Baseline (Visit 2) NT-proBNP 
Diagnosed hypertension  Visit Based hypertension 
Visit 2  









Visit 2  








<5 ng/L 4,678 3,107 1 (ref.)   <5 ng/L 
4,13
8 1,058 1 (ref.)   
5-8 ng/L  1,316 936 
 1.09  
(0.96-1.24) 0.187 5-8 ng/L  
1,12
9 351 
 1.11  
(0.98-1.26) 0.099 
9-13 ng/L  383 280 
 1.34  
(1.10-1.64) 0.003 9-13 ng/L  305 119 
 1.33  
(1.09-1.62) 0.006 
≥14 ng/L  134 96 
 1.41  
(1.02-1.93) 0.036 ≥14 ng/L  100 41 
 1.34  
(0.97-1.84) 0.075 
p-value for 
trend   <0.001   
p-value for 
trend   0.002   










*Adjusted for age (years), race-center (whites-Washington County; whites-Minneapolis; blacks-
Jackson; blacks-Forsyth County, whites-Forsyth County), sex (male or female), body mass index 
(kg/m2), smoking (current; former; never), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
triglycerides (mg/dL), estimated glomerular filtration rate (mL/min/1.73m2), current lipid-





John William McEvoy, MB BCh BAO 
Division of Cardiology, Department of Medicine, 
Johns Hopkins University School of Medicine, 
600 N. Wolfe St, Carnegie 568,  




Date of Preparation: March 26th, 2015 
Personal Data: 
Date of Birth August 26th, 1980 
Birth Place Cork, Ireland 
Citizenship Irish 






National University of Ireland, University College Cork campus  
1999-2003 
Bachelor of Medical Science 
 1st Class Honors, Mode A 
  
MB BCh BAO National University of Ireland, University College Cork campus  
1999-2004 
Bachelor of Medicine, Surgery and Obstetrics 
 1st Class Honors, Mode A 
  
M.H.S. Candidate Johns Hopkins University, Bloomberg School of Public Health 
2013-2015 (pending) 
Master of Health Science, Cardiovascular Epidemiology concentration 












July 2004- June 2005 Intern in Medicine and 
Surgery 
Cork University Hospital, Cork, Ireland 
July 2005- January 2006 Visiting Resident, Internal 
Medicine 
Mayo Clinic, Mayo Medical School, USA 
July 2005- June 2007 Senior House Officer, 
Internal Medicine 
Mater Misericordiae University Hospital, 
Dublin, Ireland 
July 2007- June 2008 Registrar, Cardiology Mater Misericordiae University Hospital, 
Dublin, Ireland 
July 2008- June 2011 Osler Residency, Internal 
Medicine- Intern, Junior 
Assistant, Senior Assistant  
Johns Hopkins Hospital, Baltimore, USA 
July 2011- June 2014 Cardiovascular Medicine 
Fellowship 
Johns Hopkins Hospital, Baltimore, USA 
July 2014- present Pollin Cardiovascular 
Prevention Fellowship 
Johns Hopkins Hospital, Baltimore, USA 







Royal College of Physicians in Ireland 
Certified Membership 2007 
  
ABIM- Internal Medicine 
 
American Board of Internal Medicine 
Board Certified 2011 
 
ABIM- Cardiovascular Diseases 
 
American Board of Internal Medicine 
 
Board Certified 2014 
  
SCCT- Cardiovascular Computed Tomography 
 
Society of Cardiovascular CT Board certification 










American Heart Association 2011- present 
  




American College of Cardiology 2011- present 
  










September 2001 Title of College Scholar  University College Cork 
September 2002 Undergraduate Scholarship, 1st place in class University College Cork 
September 2003 Undergraduate Scholarship, 1st place in class University College Cork 
September 2003 Pfizer Psychiatry Prize, 1st place in class University College Cork 
September 2003 Dr. H.H. Stewart Psychiatry Scholarship, 
                    1st place in Ireland 
National University of Ireland 
September 2004 W. Kearney Obstetrics & Gynecology Prize, 
                    1st place in class 
University College Cork 
September 2004 Dr. H.H. Stewart Surgery Scholarship, 
                    2nd place in Ireland 
National University of Ireland 
June 2005 Intern of the Year Award Cork University Hospital 
June 2013 Johns Hopkins Fellows Teaching Award Johns Hopkins Department of 
Medicine 
August 2014 Mayo Clinic CVBR Fellows Scholarship Mayo Medical School 
October 2014 Dr. Brian Maurer Young Investigator Finalist Irish Cardiac Society 
November 2014 Northwestern National Cardiovascular Young 
Investigator Award, 2nd place 
Northwestern University Chicago 
   
36 
 
Peer Reviewed Publications 
Peer Reviewed Articles Published 
McEvoy JW, Blaha MJ, Defilippis AP, Budoff MJ, Nasir K, Blumenthal RS, Jones SR. 
Coronary artery calcium progression: an important clinical measurement? A review of 
published reports. J Am Coll Cardiol. 2010 Nov 9;56(20):1613-22.  
 
McEvoy JW, Blaha MJ, Nasir K, Yoon YE, Choi EK, Cho IS, Chun EJ, Choi SI, Rivera 
JJ, Blumenthal RS, Chang HJ. Impact of coronary computed tomographic angiography 
results on patient and physician behavior in a low-risk population. Arch Intern Med. 2011 
Jul 25;171(14):1260-8.  
 
Larocca CA, McEvoy JW, Ellis CL, Junkins-Hopkins J, Kolb T, Baer AN, Garibaldi BT. 
Schnitzler's syndrome associated with pancreatitis: a disease of IL-1 dysregulation. Clin 
Rheumatol. 2012 Jan;31(1):169-74.  
 
McEvoy JW, Blaha MJ, Nasir K, Blumenthal RS, Jones SR. Potential use of coronary 
artery calcium progression to guide the management of patients at risk for coronary artery 
disease events. Curr Treat Options Cardiovasc Med. 2012 Feb;14(1):69-80.  
 
Tota-Maharaj R, McEvoy JW, Blaha MJ, Silverman MG, Nasir K, Blumenthal RS. 
Utility of coronary artery calcium scoring in the evaluation of patients with chest pain. 
Crit Pathw Cardiol. 2012 Sep;11(3):99-106.  
 
Tota-Maharaj R, Blaha MJ, McEvoy JW, Blumenthal RS, Muse ED, Budoff MJ, Shaw 
LJ, Berman DS, Rana JS, Rumberger J, Callister T, Rivera J, Agatston A, Nasir K. 
Coronary artery calcium for the prediction of mortality in young adults <45 years old and 
elderly adults >75 years old. Eur Heart J. 2012 Dec;33(23):2955-62.  
 
McEvoy JW, Blaha MJ, Rivera JJ, Budoff MJ, Khan AN, Shaw LJ, Berman DS, Raggi 
P, Min JK, Rumberger JA, Callister TQ, Blumenthal RS, Nasir K. Mortality rates in 
smokers and nonsmokers in the presence or absence of coronary artery calcification. 
JACC Cardiovasc Imaging. 2012 Oct;5(10):1037-45.  
 
Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, Joshi PH, 
Kulkarni KR, Mize PD, Kwiterovich PO, Defilippis AP, Blumenthal RS, Jones SR. 
Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and 
treatment implications. J Am Coll Cardiol. 2013 Aug 20;62(8):732-9.  
 
Chrispin J, Martin SS, Hasan RK, Joshi PH, Minder CM, McEvoy JW, Kohli P, Johnson 
AE, Wang L, Blaha MJ, Blumenthal RS. Landmark lipid-lowering trials in the primary 
prevention of cardiovascular disease. Clin Cardiol. 2013 Sep;36(9):516-23.  
 
Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, Al-Hijji MA, 
Kulkarni KR, Kwiterovich PO, Blumenthal RS, Jones SR. Non-high-density lipoprotein 
cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 
37 
 
million adults: the VLDL-2 study (very large database of lipids). J Am Coll Cardiol. 2013 
Nov 19;62(21):1960-5.  
 
Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, 
Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, 
Blumenthal RS, Jones SR. Very large database of lipids: rationale and design. Clin 
Cardiol. 2013 Nov;36(11):641-8.  
 
Shaharyar S, Warraich H, McEvoy JW, Oni E, Ali SS, Karim A, Jamal O, Blaha MJ, 
Blumenthal RS, Fialkow J, Cury R, Budoff MJ, Agatston AA, Nasir K. Subclinical 
cardiovascular disease in plaque psoriasis: association or causal link? Atherosclerosis. 
2014 Jan;232(1):72-8.  
 
McEvoy JW, Diamond GA, Detrano RC, Kaul S, Blaha MJ, Blumenthal RS, Jones SR. 
Risk and the physics of clinical prediction. Am J Cardiol. 2014 Apr 15;113(8):1429-35.  
 
Patel J, Blaha MJ, McEvoy JW, Qadir S, Tota-Maharaj R, Shaw LJ, Rumberger JA, 
Callister TQ, Berman DS, Min JK, Raggi P, Agatston AA, Blumenthal RS, Budoff MJ, 
Nasir K. All-cause mortality in asymptomatic persons with extensive Agatston scores 
above 1000. J Cardiovasc Comput Tomogr. 2014 Jan-Feb;8(1):26-32.  
 
Kim J, McEvoy JW, Nasir K, Budoff MJ, Arad Y, Blumenthal RS, Blaha MJ. 
Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the 
guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis 
Heart Trials. Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):315-22.  
 
Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy JW, Hoogeveen RC, Sharrett AR, 
Ballantyne CM, Coresh J. Diabetes mellitus, prediabetes, and incidence of subclinical 
myocardial damage. Circulation. 2014 Oct 14;130(16):1374-82. 
 
Kohli P, Whelton SP, Hsu S, Yancy CW, Stone NJ, Chrispin J, Gilotra NA, Houston B, 
Ashen MD, Martin SS, Joshi PH, McEvoy JW, Gluckman TJ, Michos ED, Blaha MJ, 
Blumenthal RS. Clinician's guide to the updated ABCs of cardiovascular disease 
prevention. J Am Heart Assoc. 2014 Sep 22;3(5):e001098. 
 
Hung RK, Al-Mallah MH, McEvoy JW, Whelton SP, Blumenthal RS, Nasir K, Schairer 
JR, Brawner C, Alam M, Keteyian SJ, Blaha MJ. Prognostic value of exercise capacity in 
patients with coronary artery disease: the FIT (Henry Ford ExercIse Testing) project. 
Mayo Clin Proc. 2014 Dec;89(12):1644-54 
 
McEvoy JW, Blaha MJ, DeFilippis AP, Lima JA, Bluemke DA, Hundley WG, Min JK, 
Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ, Blumenthal RS, Nasir K. Cigarette 
Smoking and Cardiovascular Events: Role of Inflammation and Subclinical 
Atherosclerosis from the Multiethnic Study of Atherosclerosis. Arterioscler Thromb Vasc 




Peer Reviewed Commentaries and Letters Published 
McEvoy JW, Margey R, Blake GJ. Long-term follow-up of the West of Scotland 
Coronary Prevention Study. N Engl J Med. 2008 Jan 10;358(2):193; author reply 194-5.  
 
McEvoy JW. Evolutionary game theory: lessons and limitations, a cancer perspective. Br 
J Cancer. 2009 Dec 15;101(12):2060-1; author reply 2062-3.  
 
McEvoy JW. Defibrillator implantation early after myocardial infarction. N Engl J Med. 
2010 Jan 21;362(3):269-70; author reply 270.  
 
McEvoy JW. Biventricular pacing. N Engl J Med. 2010 Mar 11;362(10):956-7; author 
reply 958-9.  
 
McEvoy JW, Blaha MJ. Progression of coronary artery calcification: not down & out. 
Arch Intern Med. 2010 Apr 26;170(8):735-6; author reply 736.  
 
McEvoy JW. Statins and risk of incident diabetes. Lancet. 2010 Jun 19;375(9732):2139; 
author reply 2141-2.  
 
McEvoy JW. What is the prognostic value of a zero calcium score? Ask Bayes! J Am 
Coll Cardiol. 2010 Aug 10;56(7):612; author replies 614-5.  
 
McEvoy JW. Coronary artery calcium score and cardiovascular event prediction. 
JAMA. 2010 Aug 18;304(7):741-2; author reply 742.  
 
McEvoy JW, Blaha MJ, Blumenthal RS. Caveat emptor: the coronary calcium warranty. 
J Am Coll Cardiol. 2010 Sep 14;56(12):997; author reply 997-8.  
 
McEvoy JW, Blaha MJ, Nasir K. "Metabolically benign" obesity: a wolf in sheep's 
clothing. Atherosclerosis. 2011 Jul;217(1):74-6.  
 
McEvoy JW. Letter by McEvoy regarding article, "Pathogenesis of sudden unexpected 
death in a clinical trial of patients with myocardial infarction and left ventricular 
dysfunction, heart failure, or both". Circulation. 2011 May 10;123(18):e585; author 
reply e586-7.  
 
McEvoy JW, Nasir K, Blumenthal RS. Calcium score reclassification: how should 
baseline risk be measured? J Am Coll Cardiol. 2011 Jun 14;57(24):2456-7; author reply 
2457.  
 
McEvoy JW. Statin therapy dose and risk of new-onset diabetes. JAMA. 2011 Sep 
28;306(12):1325-6; author reply 1326.  
 
McEvoy JW. Lifetime risks of cardiovascular disease. N Engl J Med. 2012 Apr 




McEvoy JW, Blaha MJ, Blumenthal RS. Rhinotillexis: a possible heuristic to reduce 
inappropriate noninvasive cardiac imaging? J Am Coll Cardiol. 2012 Jul 31;60(5):432; 
author reply 433.  
 
McEvoy JW, Blumenthal RS, Blaha MJ. Statin therapy for hyperlipidemia. JAMA. 2013 
Sep 18;310(11):1184-5.  
 
McEvoy JW. The Turing test and a call to action to improve electronic health record 
documentation. Am J Med. 2014 Jul;127(7):572-3.  
 
McEvoy JW, Nasir K. ABI and stroke: action at a distance and a call to action. 
Atherosclerosis. 2014 May;234(1):73-4.  
 
McEvoy JW, Blaha MJ. Coronary artery calcium testing: exploring the need for a 
randomized trial. Circ Cardiovasc Imaging. 2014 Jul;7(4):578-80 
 




Peer-reviewed Electronic Publications (online-only publications) 
 
McEvoy JW. Frontiers. University College Cork Medical Research Newsletter. Feb 
2011. 
 
McEvoy JW. The Expert Is In: New Algorithm for Patients with LBBB and Suspected 
MI. Cardioexchange: an NEJM practice community. July 2012. 
 
McEvoy JW. 2013: The Year of the Guideline. Cardioexchange: an NEJM practice 
community. January 2014. 
McEvoy JW. Article of the Month: A review of the STAMPEDE trial. ACC 
Cardiosource: Cardiometabolic Disease Community. May 2014. 
McEvoy JW. The Risk-Prediction Conundrum: Individual Risk vs. Population Risk. 
Cardioexchange: an NEJM practice community. May 2014. 
McEvoy JW. Do Doctors Need a Better Way to Take Notes? Cardioexchange: an NEJM 
practice community. August 2014. 
McEvoy JW. Debating the Lipid Guidelines. American College of Cardiology Early 
Career Newsletter. Fall 2014, Vol 1, No. 9. 
McEvoy JW. Cardiometabolic Disease “Hot Topic”: My thoughts regarding the article, 
“Further Insight Into the Cardiovascular Risk Calculator: The Roles of Statins, 
Revascularizations, and Underascertainment in the Women’s Health Study” by Cook et 




Books and Book Chapters Published 
McEvoy JW, Tota-Maharaj R, Blaha MJ. Metabolic Syndrome: Understanding the 
Epidemic in India and South Asia. Book. MacMillan Medical Communications. 2013 
 
McEvoy JW, Blumenthal RS, Michos ED. Pathophysiology and Pharmacotherapy of 
Cardiovascular Disease. “Cardiac Prevention Guidelines”. Chapter. Springer 





McEvoy JW, Blaha MJ, DeFilippis AP, Lima JA, Bluemke DA, Hundley WG, Min JK, 
Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ, Blumenthal RS, Nasir K. Cigarette 
Smoking: Association Between Inflammation, Subclinical Atherosclerosis and 
Cardiovascular Events. The Multi-Ethnic Study of Atherosclerosis (MESA). American 
Heart Association Scientific Sessions, Oral Abstract 9726, November 2011. 
 
McEvoy JW, Blaha MJ, DeFilippis AP, Lima JA, Bluemke DA, Hundley WG, Min JK, 
Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ, Blumenthal RS, Nasir K. Cigarette 
Smoking: Association Between Inflammation, Subclinical Atherosclerosis and 
Cardiovascular Events. The Multi-Ethnic Study of Atherosclerosis (MESA). Irish 
Cardiac Society Annual Conference Oral Presentation. October 2012. 
 
McEvoy JW. Screening for Coronary Artery Disease: A State of the Art. Cork 
University Hospital Medical Grand Rounds, May 2013. 
 
McEvoy JW, Blaha MJ, DeFilippis AP, Lima JA, Bluemke DA, Hundley WG, Min JK, 
Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ, Blumenthal RS, Nasir K. Cigarette 
Smoking: Relationship with Inflammation, Arterial Stiffness, and Subclinical 
Atherosclerosis. The Multi-Ethnic Study of Atherosclerosis (MESA). Irish Cardiac 
Society Annual Conference, Brian Maurer Young Investigator Finalist Oral Presentation. 
October 2014. 
 
McEvoy JW, Lazo M, Shen L, Nambi V, Hoogeveen RC, Ballantyne C, Blumenthal RS, 
Coresh J, Selvin E. Cardiac Risk Factors and 6-Year Change in high-sensitivity Cardiac 
Troponin-T from ARIC. Northwestern University National Cardiovascular Young 
Investigator Finalist Oral Presentation. November 2014. 
 
McEvoy JW. High sensitivity troponin and hypertension- post hoc or propter hoc? 







McEvoy JW, Blaha MJ, DeFilippis AP, Lima JA, Bluemke DA, Hundley WG, Min JK, 
Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ, Blumenthal RS, Nasir K. Cigarette 
Smoking: Relationship with Inflammation, Arterial Stiffness, and Subclinical 
Atherosclerosis. The Multi-Ethnic Study of Atherosclerosis (MESA). American Heart 
Association Scientific Sessions, Poster Abstract 9713, November 2011. 
 
McEvoy JW, Lazo M, Shen L, Nambi V, Hoogeveen RC, Ballantyne CM, Blumenthal 
RS, Coresh J, Selvin E. Cardiac Risk Factors and 6-Year Change in high-sensitivity 
Cardiac Troponin-T from ARIC. American Heart Association: Epidemiology and 
Prevention, Lifestyle and Cardiometabolic Health Scientific Sessions, Poster Abstract, 
March 2014. 
 
McEvoy JW, Martin SS, Blaha MJ, Joshi PH, Manning S, Blumenthal RS, Jones SR. 
The Relationship between Thyroid dysfunction and Advanced Lipoprotein Cholesterol 
Subfractions in a Contemporary Sample of US Adults: The Very Large Database of 
Lipids Thyroid Substudy. American College of Cardiology Scientific Session, Poster 
Abstract, March 2014. 
 
McEvoy JW, Chen Y, Nambi V, Ballantyne CM, Sharrett AR, Appel LJ, Post WS, 
Blumenthal RS, Matsushita K, Selvin E. Baseline High-sensitivity Cardiac Troponin-T is 
independently associated with Incident Hypertension. American Heart Association: 
Epidemiology and Prevention, Lifestyle and Cardiometabolic Health Scientific Sessions, 




Editorial Commitments  
Editorial Board 
Editorial Fellow, British Medical Journal  
April 2013- present. 
Supervisor: Jose Merino MD, BMJ U.S. Clinical Research Editor  
 
Journal Peer Reviewer 
 
British Medical Journal 
New England Journal of Medicine 
Journal of the American Medical Association 
Archives of Internal Medicine (JAMA-Internal Medicine) 
Journal of the American College of Cardiology 
Journal of the American College of Cardiology: Cardiovascular Imaging 
Circulation 





Fellowship and Grant Support 
Pollin Cardiovascular Prevention Fellowship. Annual Stipend and Tuition support for 
MHS Degree. 
Co-investigator. Patient Centered Outcomes Research Institute. Demonstrating respect 
and acceptable consent strategies:  What matters to patients in PCOR? Principle 
Investigator: Nancy Kass ScD. Funding amount: $1,678,250 
Co-investigator. Magic That Matters Fund, Johns Hopkins Division of Cardiology. 
Pathogenic HDL: An Alternative Lox-1 Receptor Ligand Induces Endothelial 
Dysfunction. $15,000 Salary Support. Principle Investigator: Dan Berkowitz MD PhD.  
 
Mentorship 
Original Investigation Mentorship 
Jaideep Patel, MD. Assistant Clinical Professor, Department of Internal Medicine, 
Virginia Commonwealth Medical Center 
Amer I. Aladin, MD. Ciccarone Center for the Prevention of Heart Disease, Johns 
Hopkins School of Medicine, Baltimore, MD 
 
Teaching Experience 
Graduate Medical Education 
Graduate Medical Education 
Activity description: Lecture, “Cardiac Hemodynamics Lecture”. 
Role: Teacher/Presenter 
Learners:  50 /year (undergraduate medical students and residents) 
Time Frame:  2014-present 
 
Graduate Medical Education 
Activity description: Lecture, “Vasoactive Medications: 101”. 
Role: Teacher/Presenter 
Learners:  50 /year (undergraduate medical students and residents) 
Time Frame:  2014-present 
 
Graduate Medical Education 
Activity description: Lecture, “Anti-arrhythmic Medications”. 
Role: Teacher/Presenter 
Learners:  50 /year (undergraduate medical students and residents) 




Graduate Medical Education 
Activity description: SIMULATION- Medical resident vascular access. 
Role: Teacher/Presenter 
Learners:  40 /year (Medical residents) 
Time Frame:  2014-present 
 
Graduate Medical Education 
Activity description: Fellow’s Noon Conference Didactic Lecture Series 
Role: Director/ Organizer/ Facilitator 
Learners:  30 /year (cardiology fellows) 
Time Frame:  2014-2015. Two lectures per week over the academic year 
 
Graduate Medical Education 
Activity description: Fellow’s Case Conference Series 
Role: Contributor  
Learners: 30 /year (cardiology fellows) 
Time Frame: 2011-present. One conference per week over academic year 
 
Summary of Teaching Activities:   
 500 hours/year contact time with students  
 Lead sessions on varied topics in cardiology, discussed above. 
 Provided clinical precepting for students and residents on both the General Cardiology 
and CCU clinical service 
 
